StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note published on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Down 5.2 %
NASDAQ:TTNP opened at $3.54 on Monday. Titan Pharmaceuticals has a one year low of $3.03 and a one year high of $14.80. The company has a fifty day moving average price of $3.60 and a 200 day moving average price of $4.09.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Ride Out The Recession With These Dividend Kings
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
